Trials / Completed
CompletedNCT05677893
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Oneness Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBS-COV | MBS-COV is a potent siRNA treatment for mild to moderate COVID-19. |
| OTHER | Placebo | Normal saline |
Timeline
- Start date
- 2022-11-07
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
- First posted
- 2023-01-10
- Last updated
- 2025-03-30
- Results posted
- 2025-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05677893. Inclusion in this directory is not an endorsement.